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Case ReportsLeft ventricular assist device thrombosis presenting as an acute
coronary syndromeNavin K. Kapur, MD, Jenica Upshaw, MD, Michael S. Kiernan, MD, and Duc Thinh Pham, MD,
Boston, MassVideo clip is available online.
Left ventricular (LV) assist device (LVAD) thrombosis is a
major cause of morbidity among LVAD recipients.1 Hemo-
dynamic instability, heart failure symptoms, and complica-
tions related to systemic thromboembolism are common
manifestations of acute LVAD failure.2 We report a case
of presumed LVAD thrombosis presenting as an acute
coronary syndrome.
CLINICAL SUMMARY
A 63-year-old woman with ischemic cardiomyopathy
required placement of a HeartMate II (Thoratec Corpora-
tion, Pleasanton, Calif) LVAD as destination therapy. Two
years later, she came to her local emergency department
with acute onset of crushing chest pain and dyspnea. An
admission electrocardiogram showed ventricular pacing,
only without new ST-segment elevation. A continuous
hum throughout the precordiumwas noted, along with biba-
silar rales. Laboratory analysis showed an elevated troponin
I value and hemolysis (Table 1). Echocardiography showedTABLE 1. Hemodynamic, laboratory, and left ventricular assist device pa
Hemodynamic variables
MAP
(mm Hg)
HR
(beats/min)
RA
(mm Hg)
PAP
(mm Hg)
PCWP
(mm Hg)
CI
(L/min/m2)
Admission 70 97 2 19/8 3 2.3
Pre-tPA 74 80 2 20/12 16 2.6
Post-tPA 90 80 2 22/6 4 4.5
LVAD, Left ventricular assist device;MAP, mean arterial pressure; HR, heart rate; RA, right
pressure; CI, cardiac index; LDH, lactate dehydrogenase; TB, total bilirubin; pf Hb, plasma
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e72 The Journal of Thoracic and Cardiovascular Surga dilated LVand opening of the aortic valve with every car-
diac cycle.3 Coronary angiography was deferred, and right
heart catheterization showed low right and left heart filling
pressures and a low normal cardiac index (Table 1). Initial
management included unfractionated heparin, aspirin, and
clopidogrel for a possible cardioembolic myocardial infarc-
tion and presumed LVAD thrombosis. After initial stabiliza-
tion on medical therapy, the patient had hypotension and
worsening dyspnea without chest pain develop on hospital
day 5 (Table 1). Transesophageal echocardiography showed
no aortic or LV thrombus and limited Doppler flow across
the LVAD inflow conduit (Video 1). Coronary angiography
through the right radial artery was unchanged relative to a
previous study (Figure 1, A, and Video 2). Initial LV pres-
sure was 79/8 mmHg, confirming incomplete LVunloading
(Figure 1, B and C). Left ventriculography showed patent
inflow and outflow LVAD conduits (Video 3). Collectively,
these findings suggested the diagnosis of presumed LVAD
thrombosis. LVAD exchange was deferred because of se-
vere peripheral vascular disease and multiple prior sternot-
omies. Alteplase (1 mg/min) was infused into the LV
without an initial bolus through a pigtail catheter with inter-
mittent monitoring of LV pressures (Figure 1, A). After 28
minutes of infusion, LV pressure decreased to 19/2 mm
Hg, with an aortic pressure of 110/85 mm Hg, indicating
successful LVAD thrombolysis (Figure 1, B and C). Alte-
plase was continued for a total of 42 minutes. LVAD param-
eters showed increased flow, a reduced pulsatility index,
and closure of the aortic valve (Table 1). During the next
several days, hemolysis parameters improved (Figure 2),
and the patient was discharged on hospital day 12 with
aspirin, clopidogrel, and warfarin. Lactate dehydrogenase
levels remained less than 500 IU/L 1 month after discharge.
DISCUSSION
Nearly 1500 LVADs are implanted annually in the United
States alone.4 The diagnosis and management of LVADrameters
Laboratory studies LVAD parameters
LDH
(IU/L)
TB
(mg/dL)
pf Hb
(mg/dL)
Tn I
(ng/dL)
Speed
(rpm)
Flow
(L/min)
Power
(W) PI AV
1380 1.1 33.6 27.4 — — — — —
4136 2.3 75.1 9.25 9200 4.1 8.7 5.2 Opening
1957 0.3 6.4 8.47 9800 6.1 7.1 3.5 Closed
atrial pressure; PAP, pulmonary arterial pressure; PCWP, pulmonary capillary wedge
free hemoglobin; Tn I, troponin I; PI, pulsatility index; AV, aortic valve; tPA, alteplase.
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FIGURE 1. Intracavitary left ventricular (LV) assist device thrombolysis. A, Radial artery access with a 6F pigtail catheter in the left ventricle and a 3-way
stopcock for intermittent left ventricular hemodynamicmonitoringwith a fluid-filledmanometer during thrombolytic infusion. B, Left ventricular pressures at
baseline andduring thrombolytic infusion, showinga gradual reduction in both left ventricular systolic anddiastolic pressures (shownas systolic/diastolic, end-
diastolic pressure). C, Left ventricular hemodynamic tracings before and after alteplase (tPA) infusion, followed by a pullback sequence from the left ventricle
to the aorta, showing a step up in systolic and diastolic pressures and suggesting improved left ventricular unloading by the left ventricular assist device.
Case Reportsdysfunction remains poorly understood. Our report has
several potentially important clinical implications. First,
we identify acute coronary syndrome as a potential
manifestation of LVAD failure. Acute coronary syndrome
in patients with LVADs may be due to coronary thrombosis,
cardioembolus, or primary LVAD failure leading to demand
ischemia. Second, emergency coronary revascularization in
this complex clinical scenario carries a risk of bleeding,
systemic thromboembolism, and worsening hemodynamic
instability. For this reason, initial angiography was
deferred, and instead the diagnosis of presumed LVAD
thrombosis, likely caused by bearing thrombosis, was
investigated by studying LVAD parameters, laboratory evi-
dence of hemolysis, imaging studies to rule out aortic root
or intracavitary thrombosis, and invasive hemodynamicFIGURE 2. Serum lactate dehydrogenase (LDH) levels before and after
intracavitary thrombolysis.
The Journal of Thoracic and Cameasurements. Third, this case demonstrates that right heart
catheterization alone may be insufficient to diagnose
LVAD dysfunction. Instead, left ventriculography with
intracavitary hemodynamics may be a helpful alternative
to evaluate LVAD function. Finally, fibrinolytic therapy is
often a temporary solution and carries a high rate of
recurrent thrombosis. LVAD exchange remains the criterion
standard for the treatment of LVAD thrombosis; however,
not all patients are candidates for LVAD exchange. We
report our approach to intracavitary thrombolysis through
the radial artery with intermittent monitoring of LV
pressures.
In conclusion, acute LVAD thrombosis complicated by
an acute coronary syndrome may be successfully managed
by intracavitary thrombolysis in select cases. A careful
assessment of LVAD function and management options
must involve consultation with an interventional cardiolo-
gist, a heart failure specialist, and a cardiac surgeon.References
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